Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome.
Plioplys, A V, Plioplys, S · Neuropsychobiology · 1997 · DOI
Quick Summary
This study tested whether two medicines—L-carnitine and amantadine—could help reduce fatigue in ME/CFS patients. Researchers gave 30 patients each medicine for 2 months to compare which worked better. L-carnitine was well-tolerated and showed improvement in most measured symptoms, while amantadine caused side effects that forced half the patients to stop taking it.
Why It Matters
This is one of the first formal investigations of L-carnitine for ME/CFS, providing evidence that a low-toxicity, mitochondrial-supporting agent may improve multiple clinical parameters in this population. The finding that carnitine supplementation targets a plausible metabolic mechanism—impaired mitochondrial energy production—offers a rational therapeutic approach worth further investigation.
Observed Findings
L-carnitine produced statistically significant improvement in 12 of 18 clinical parameters after 8 weeks of treatment
Amantadine was discontinued by 15 of 30 patients (50%) due to adverse effects, compared to only 1 patient on L-carnitine
In the 15 amantadine completers, no statistically significant improvement was observed in any clinical parameter
No clinical parameters showed deterioration with L-carnitine treatment
Greatest clinical improvement occurred between weeks 4 and 8 of L-carnitine treatment
Inferred Conclusions
L-carnitine is a safe, well-tolerated therapeutic option for ME/CFS patients that produces clinically meaningful improvements
Amantadine's poor tolerability and lack of efficacy in completers suggest it is not suitable for ME/CFS treatment
Improved mitochondrial energy production via carnitine supplementation may address an underlying pathophysiologic mechanism in ME/CFS
L-carnitine's delayed onset (peak benefit weeks 4-8) suggests a gradual biochemical restoration process
Remaining Questions
What is the optimal dose and duration of L-carnitine treatment, and does benefit persist long-term?
What This Study Does Not Prove
This study does not prove L-carnitine cures ME/CFS or that it works for all patients; the lack of a placebo control means improvement could partly reflect placebo effect or natural fluctuation in symptoms. It also does not establish that low carnitine levels *cause* ME/CFS fatigue, only that supplementation correlates with symptom improvement. The small sample and 1997 publication date mean findings require replication in larger, modern trials.
Tags
Symptom:Fatigue
Biomarker:Metabolomics
Method Flag:PEM Not DefinedWeak Case DefinitionSmall Sample
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Does pre-treatment carnitine level predict treatment response, and should testing be used to select patients?
What is the mechanism of L-carnitine's benefit—restoration of mitochondrial function, immune modulation, or another pathway?
How much of the observed improvement was due to placebo effect versus specific carnitine activity, and would a larger placebo-controlled trial show sustained benefit?